TABLE 2.
Cross‐sectional studies characteristics
| Study | Total sample | Age | Disease duration | Months post‐operative | Newcastle‐Ottawa score | Apathy scale | Score STN DBS group | Score control group | LEDD difference (%) |
| Crespo‐Burillo et al 62 | 22 | 65.4 ± 7.7 | 21.2 ± 13.1 | 3 | 6 | SAS | 11.6 ± 7.1 | 11.4 ± 5.5 | NR |
| Czernecki et al 63 | 41 | 57.8 ± 1.8 | 13.9 ± 1.6 | 10 | 8 | SAS | 11.2(0.9) | 11.0(1.5) | −86.4 |
| Drapier et al 43 | 30 | 59.7 ± 7.6 | 12.2 ± 2.8 | 6 | 7 | SAS & AES | 18.8 ± 9.7 | 13.0 ± 6.5 | −22.2 |
| Enrici et al 64 | 38 | 60.3 ± 7.6 | 12.0 ± 6.8 | NR | 6 | SAS | 11.9 ± 3.6 | 12.8 ± 5.6 | −29.2 |
| Evens et al 65 | 66 | 65.5 ± 7.3 | 11.3 ± 6.2 | 3 | 6 | SAS | 15.5 ± 6.4 | 8.9 ± 4.7 | +6.3 |
| Hindle Fisher et al 66 | 60 | 66.3 ± 3.1 | 10.3 | 6 | 8 | SAS & LARS | 13.8 ± 4.7 | 12.1 ± 6.3 | −15.1 |
| Houvenaghel et al 67 | 50 | 57.8 ± 7.7 | 12.2 ± 3.3 | 30 | 5 | AES | 30.3 ± 8.8 | 27.5 ± 6.7 | −30.2 |
| Kojovic et al 68 | 20 | 59.3 | 9.4 ± 5 | NR | 5 | AES | 38.5 ± 2.2 | 32.2 ± 2.8 | −18.6 |
| Leimbach et al 69 | 24 | 63.6 ± 11.3 | NR | 3 | 8 | SAS | 15.0 ± 5.5 | 10.5 ± 5.3 | NR |
| Lhommee et al 41 | 251 | 52.5 ± 6.3 | 7.5 ± 2.9 | 24 | 8 | SAS | 12.7(0.5) | 11.4(0.5) | −48.2 |
| Mcdonald et al 70 | 34 | 57.4 ± 6.5 | 13.5 ± 5.2 | 14.5 | 8 | SAS | 13.0 ± 11.6 | 10.3 ± 6.4 | −12.6 |
| Okun et al 71 a | 30 | 59 ± 8.6 | 11.8 ± 3.9 | 6 | 8 | SAS | 16.4 ± 9.3 | 13.1 ± 6.0 | −17.2 |
| Valldeoriola et al 42 | 23 | 57.9 ± 4.8 | 13.7 | 6 | 5 | LARS | −27 ± 21.6 | −9 ± 15.8 | −21.4 |
Follow‐up, apathy assessment follow‐up in months after the STN DBS operation. Studies with the variance marked as ± reported standard deviations, studies with brackets () reported the standard error. Abbreviations: LEDD, levodopa equivalent daily dosage; SAS, Starkstein Apathy Scale; AES, Apathy Evaluation Scale; LARS, Lille Apathy Rating Scale; NR, not reported.
a
One study used unilateral stimulation, all other studies used bilateral stimulation.